中文 | English
Return
Total: 6 , 1/1
Show Home Prev Next End page: GO
Author:(Ruirui BU)

1.Comparative analysis ofapplication value and setup error between two setup methods in proton and carbon ion therapy for prostate cancer

Huaguo SONG ; Ruirui BU ; Yongqiang LI ; Wei REN ; Shen FU

Chinese Journal of Radiation Oncology 2018;27(4):382-386

2. Feasibility of amplicon-based targeted next-generation sequencing of colorectal cancer in endoscopic biopsies

Yajian WANG ; Ruirui JIANG ; Haijing LIU ; Bo ZHANG ; Feng YE ; Hong BU

Chinese Journal of Pathology 2018;47(7):499-504

3. Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples

Ruirui JIANG ; Yajian WANG ; Xiaodong TENG ; Lin XIAO ; Hong BU ; Feng YE

Chinese Journal of Pathology 2018;47(8):591-596

4.Xihuangwan Inhibits Mitochondrial Energy Metabolism in Ovarian Cancer Cells

Xianxin YAN ; Shouyi HONG ; Ruirui MA ; Yanqiu WANG ; Junyi BU ; Min MA

Chinese Journal of Experimental Traditional Medical Formulae 2024;30(1):70-76

5.Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1-BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy.

Xin YUE ; Tingyu LIU ; Xuecen WANG ; Weijian WU ; Gesi WEN ; Yang YI ; Jiaxin WU ; Ziyang WANG ; Weixiang ZHAN ; Ruirui WU ; Yuan MENG ; Zhirui CAO ; Liyuan LE ; Wenyan QIU ; Xiaoyue ZHANG ; Zhenyu LI ; Yong CHEN ; Guohui WAN ; Xianzhang BU ; Zhenwei PENG ; Ran-Yi LIU

Acta Pharmaceutica Sinica B 2023;13(8):3382-3399

6.A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance.

Lei SUN ; Arabella H WAN ; Shijia YAN ; Ruonian LIU ; Jiarui LI ; Zhuolong ZHOU ; Ruirui WU ; Dongshi CHEN ; Xianzhang BU ; Jingxing OU ; Kai LI ; Xiongbin LU ; Guohui WAN ; Zunfu KE

Acta Pharmaceutica Sinica B 2024;14(1):223-240

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 6 , 1/1 Show Home Prev Next End page: GO